Abstract
The value of maternal periconceptional vitamin supplementation in preventing the conception of fetuses with neural tube defects has yet to be assessed in a properly designed study. Avoidance of the birth of affected infants continues to rest on second‐trimester maternal serum alphafetoprotein screening. The performance of screening programmes in achieving this objective is reviewed.